C4X Discovery (C4XD) Share Price, News & Analysis

Company Overview

C4X Discovery Holdings plc operates as drug discovery company in the United Kingdom. The company provides Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing 4D molecules in virtual reality research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules. Its product pipeline includes Orexin-1, a receptor antagonist for the treatment of addictive disorders; NRF-2 activator to treat various inflammatory diseases; IL-17A inhibitor for inflammation diseases; a4ß7 integrin inhibitors for the treatment of inflammatory bowel disease; and MALT-1 inhibitors to treat hematological cancer. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. C4X Discovery Holdings plc was incorporated in 2007 and is based in Manchester, the United Kingdom.

Key Stats

• Today's Range: 8.30 to 12
• 50-Day Range: 12 to 12
• 52-Week Range: 7 to 22
• Volume: 3.77 million shs
• Average Volume: 1.18 million shs
• Market Capitalization: £30.27 million
• P/E Ratio: 300.00
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

C4XD Stock Analysis - Frequently Asked Questions

How have C4XD shares performed this year?

C4X Discovery's stock was trading at GBX 9 on January 1st, 2024. Since then, C4XD stock has increased by 33.3% and is now trading at GBX 12.
View the best growth stocks for 2024 here.

How were C4X Discovery's earnings last quarter?

C4X Discovery Holdings plc (LON:C4XD) released its quarterly earnings results on Wednesday, April, 29th. The company reported ($5.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.50) by $0.48. C4X Discovery had a net margin of 42.81% and a trailing twelve-month return on equity of 55.38%.

How do I buy shares of C4X Discovery?

Shares of C4XD stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of C4X Discovery own?

Based on aggregate information from My MarketBeat watchlists, some other companies that C4X Discovery investors own include The Berkeley Group (BKG), B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC) and Intel (INTC).

Company Calendar

• Last Earnings: 4/29/2020
• Today: 11/04/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:C4XD
• CUSIP: N/A
• CIK: N/A
• Web: www.c4xdiscovery.com
• Phone: +44-161-2355085
• Fax: N/A
• Employees: 49
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX 0.04
• Trailing P/E Ratio: 300.00
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £10.57 million
• Net Margins: 42.81%
• Pretax Margin: N/A
• Return on Equity: 55.38%
• Return on Assets: 28.04%

Debt

• Debt-to-Equity Ratio: 1.05
• Current Ratio: 15.31
• Quick Ratio: 9.82

Sales & Book Value

• Annual Sales: £24.68 million
• Price / Sales: 1.23
• Cash Flow: GBX 3 per share
• Price / Cash Flow: 4.00
• Book Value: GBX 10 per share
• Price / Book: 1.20

Miscellaneous

• Outstanding Shares: 252,230,000
• Free Float: N/A
• Market Cap: £30.27 million
• Optionable: Not Optionable
• Beta: 0.23